



Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)

Paul Richardson¹ · Saurabh Aggarwal² · Ozlem Topaloglu² · Kathleen F. Villa³ · Selim Corbacioglu⁴

Published online: 1 April 2019
© The Author(s) 2019

Correction to: Bone Marrow Transplantation

<https://doi.org/10.1038/s41409-019-0474-8>
published online 25 Feb 2019

The original version of this article included some minor typesetting errors in Table 1—a corrected version of which is provided in this correction article and has been corrected in

the original article—and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as ‘Springer Nature Limited’, however, since the article is Open Access, the copyright holders should in fact be ‘The Author(s)’. This has also been corrected in the original article.

✉ Saurabh Aggarwal
sa2@novelhealthstrategies.com

¹ Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

² Novel Health Strategies, Bethesda, MD, USA

³ Jazz Pharmaceuticals, Inc, Palo Alto, CA, USA

⁴ Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany

Table 1 Summary of report characteristics, patient demographics, transplant type, and disease parameters

Reference*	Study quality factors		Defibrotide-treated			Age		Transplant		Common underlying diseases			
	Prospective?	Type	Total	MOD	No MOD	Median	≤ 16 years	> 16 years	Auto	Allo	ALL	AML	Other
Richardson 1998 [1]	Yes	Single center	19	19	0	40	3	16	11	8	1	3	15
Chopra 2000 [2]	Yes	CU	40	26	14	30	11	29	14	26	6	14	20
Richardson 2002 [3]	Yes	CU	88	88	0	35	29 ^a	59 ^a	28	60	6	22	60
Corbacioglu 2004 [4]	No	CU	45	22	23	8.2	40	5	8	37	6	10	29
Bulley 2007 [5]	No	Single center	14	NR	NR	10.2	14 ^b	0 ^b	0	14	3	1	10
Sucak 2007 [6]	No	Single center	14	6	8	40.5	0 ^b	14 ^b	1	13	4	5	5
Richardson 2010 [7]	Yes	Phase 2, dose finding	149	149	0	34	48 ^a	101 ^a	20	129	15	47	87
Ruiz Ramos 2014 [8]	No	Observational	11	NR	NR	NR	4	5	NR	NR	NR	NR	NR
Locatelli 2015 [9]	Yes	CU	98	17	77	13.4	52 ^a	42 ^a	10	75	18	23	57
Triplet 2015 [10]	Yes	Single center	34	22	12	8.9	31 ^a	3 ^a	2	29	10	10	14
Balade Martinez 2016 [11]	No	Observational	42	42	0	46	12	30	NR	NR	NR	NR	NR
Corbacioglu 2016 [12]	Yes	CU	710	261	348	25	303 ^a	407 ^a	112	499	120	177	413
Pol 2016 [13]	No	Single center	13	12	1	60.5	0	13	0	13	0	7	6
Richardson 2016 [14]	Yes	Phase 3	102	102	0	21	44	58	12	90	17	29	56
Strouse 2016 [15]	No	Registry	41	41	0	11	25 (61)	16 (39)	2 (5)	39 (95)	19 ^c	NR	22
Yakushijin 2016 [16]	No	Registry	24	NR	NR	40	NR	NR	0	65	NR	NR	NR
Richardson 2017 (T-IND) [17]	Yes	T-IND	1154	571	NR	12	691	463	155	843	279	279	596

ALL, acute lymphocytic leukemia; Allo, allogeneic; AML, acute myelogenous leukemia; Auto, autologous; CU, compassionate use; MOD, multi-organ dysfunction; NR, not reported; T-IND, defibrotide expanded access program

^aPediatric defined as ≤ 18 years and adults as > 18 years

^bInclusive of age 16 years

^cAcute leukemias

*These references are listed in accordance with the correction article, however in the original article the reference numbers differ, as they are in accordance with the original article

References

1. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. *Blood*. 1998;92:737–44.
2. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. *Br J Haematol*. 2000;111:1122–9.
3. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. *Blood*. 2002;100:4337–43.
4. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. *Bone Marrow Transplant*. 2004;33:189–95.
5. Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. *Pediatr Blood Cancer*. 2007;48:700–4.
6. Sucak GT, Aki ZS, Yagci M, Yegin ZA, Ozkurt ZN, Haznedar R. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. *Transplant Proc*. 2007;39:1558–63.
7. Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. *Biol Blood Marrow Transplant*. 2010;16:1005–17.
8. Ruiz Ramos J, Company Albir MJ, Favieres Puigcerver C, Marrero Álvarez P, Megias Vericat JE, Valero García S, et al. CP-129 Defibrotide for sinusoidal obstruction syndrome: a single centre experience. *Eur J Hosp Pharm*. 2014;21:A52.
9. Locatelli F, Faraci M, Cesaro S, Pagliara D, Fagioli F, Zecca Marco, et al. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following hematopoietic stem cell transplantation or chemotherapy—results from the Italian Therapeutic Use Protocol. *Blood*. 2015;126:3107.
10. Triplett BM, Kuttub HI, Kang G, Leung W. Escalation to high-dose defibrotide in patients with hepatic veno-occlusive disease. *Biol Blood Marrow Transplant*. 2015;21:2148–53.
11. Balade Martinez L, Valle LGD, Martin ER, De Sebastian Rueda M, Molia Cabezuelo M, Herrero Ambrosio A. CP-062 Defibrotide for the treatment of severe hepatic veno-occlusive disease. A single centre experience. *Eur J Hosp Pharm*. 2016;23:A27–A28.
12. Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. *Biol Blood Marrow Transplant*. 2016;22:1874–82.
13. Pol RR, Russell N, Das-Gupta E, Watson L, Rachael L, Byrne J. Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide. *Bone Marrow Transplant*. 2016;51:1262–4.
14. Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. *Blood*. 2016;127:1656–65.
15. Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, et al. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant*. 2016;22:1306–12.
16. Yakushijin K, Ikezoe T, Ohwade C, Kudo K, Okamura H, Goto H, et al. Nationwide survey of defibrotide and recombinant human soluble thrombomodulin for treatment of sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2016;51:S77–S78.
17. Richardson P, Smith A, Triplett B, Kernan N, Grupp S, Antin J, et al. Final efficacy and safety results from a defibrotide expanded-access program for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. *Bone Marrow Transplant*. 2017;52:S64–S65.